Navigation Links
Provectus Pharmaceuticals, Inc.'s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Date:5/7/2012

NEW YORK, May 7, 2012 /PRNewswire/ -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, today announced that its May 3rd RetailInvestorConferences.com presentation is now available for on-demand viewing.

LINK: www.retailinvestorconferences.com > red "register/ watch event now" button

Provectus Pharmaceuticals, Inc's presentation will be available for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.

About Provectus Pharmaceuticals Inc.

Provectus Pharmaceuticals (PVCT) specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.

About RetailInvestorConferences.com

Since 2010, RetailInvestorConferences.com, created by BetterInvesting (NAIC) PR Newswire and MUNCmedia, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a
'/>"/>

SOURCE Provectus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Solta Medical Receives Provectus Innovation Award at MDB Capital Groups Bright Lights Intellectual Property Conference
2. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
3. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
4. Avion Pharmaceuticals, LLC Names Michael Sullivan as new VP, Sales and Marketing
5. Auxilium Pharmaceuticals, Inc. and FCB I LLC Receive Paragraph IV Certification Notice from Watson Laboratories, Inc. for Testim®
6. Gamma Pharmaceuticals, Inc. Announces Distribution Agreement for New York Tri-state Area and Purchase Order for Gamma Energy GEL™
7. Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult Cancer Patients Being Treated for Clostridium difficile-Associated Diarrhea (CDAD)
8. Gamma Pharmaceuticals, Inc. Announces Key Appointment in Sales and Marketing
9. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2011 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year-End 2011 Financial Results
11. Tibet Pharmaceuticals, Inc. Announces Intent to Go Private
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... EMERYVILLE, Calif. , June 19, 2013 /PRNewswire/ ... performance management solutions, introduced the next-generation of its ... solution, which allows health plans to provide their ... their populations, health factors, medical and prescription drug ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) ...
(Date:6/19/2013)... June 19, 2013  It may seem like an odd ... breast cancer. But these were two of the most talked ... Annual Meeting & Expo that just convened in ... this focus by some of the top internal medicine experts ... with new research that can not only save lives, but ...
(Date:6/18/2013)... NEW YORK , June 18, 2013  Intercept ... stage biopharmaceutical company focused on the development and commercialization ... diseases, today announced the pricing of an underwritten public ... a public offering price of $33.01 per share.  In ... to purchase up to an additional 259,500 shares of ...
Breaking Medicine Technology:MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... (Nasdaq: DVAX ) today reported that it had ... subjects as,part of an environmental exposure chamber study that ... are being screened based on a history of,ragweed allergy ... in,the chamber is being used to select those individuals ...
... Demonstrate Continued Safety, Consistently Positive Clinical ... ... presented today from,Abbott,s SPIRIT III U.S. pivotal clinical trial demonstrated ... Coronary Stent System at one year, including continued,clinical superiority in ...
Cached Medicine Technology:Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study 2Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study 3Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 2Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 3Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 4Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 5
(Date:6/19/2013)... June 19, 2013 The deadline ... is this Friday, June 21 at midnight ET. ... programs and innovative people who’ve raised the bar ... visit http://www.minonline.com/ima . , Any consumer and ... title is eligible to enter. Additionally, advertising agencies ...
(Date:6/19/2013)... Utah (PRWEB) June 19, 2013 Today, ... Wisconsin Health Insurance Exchange . Zane Benefits, which provides ... benefits, is the leader in defined contribution ... to Zane Benefits’ website, as part of the Affordable ... small businesses will become available through new state health ...
(Date:6/19/2013)... Lawrence, KS (PRWEB) June 19, 2013 ... photographs is common with today’s computer software, it creates ... a form of misconduct. As an already published case ... of photo manipulation. , The Journal of Parasitology ... image manipulation in a 2004 article published in ...
(Date:6/19/2013)... results of three important studies have been published in ... of the Congress of Neurological Surgeons . ... Wilkins , a part of Wolters Kluwer Health ... using artificial neural networks (ANNs) may improve the ability ... Another study in the June Neurosurgery supports ...
(Date:6/19/2013)... 19, 2013) In early April, senior leaders from ... Hartford, Connecticut, to discuss one question: how can first ... , The preliminary results of this discussion are ... Events: The Hartford Consensus ," a concept paper published ... Journal of Trauma and Acute Care Surgery , ...
Breaking Medicine News(10 mins):Health News:Entry Deadline for min’s Integrated Marketing Awards Is This Friday, June 21 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Hartford consensus aims to improve survival after mass shootings 2
... 2009 Laboratory market projections.NEWARK, N.J., April 14 ... G-2 Reports indicates that the clinical diagnostic lab ... by 2017. An increase in genetic testing, ... expanded access to healthcare are among the key ...
... Maine, April 14 IDEXX Laboratories, Inc. (Nasdaq: ... 2009 first quarter financial results for Friday, April 24, at ... conference call beginning at 9:00 a.m. (eastern) on that day. ... through a link on the IDEXX Web site, ...
... & Spa,Group, Inc. (OTC Bulletin Board: SOKF), a leading operator ... CEO Liu, Tong, CFO Yu, Xia,and corporate secretary Mu, Yan ... earnings results at 9 am EDT on Thursday,April 16, 2009. ... * US/Canada Toll Free Dial-in #: (866) 811 - 8933, ...
... related blindness by almost 35%, study suggests, , , TUESDAY, ... age-related macular degeneration is on the increase, newer treatments ... disease by about 35 percent, new estimates suggest. , ... Disease Control and Prevention, researchers report that as many ...
... Six New Board of Directors Members Also Appointed and ... Bruce R. Korf, MD, PhD, FACMG, of Birmingham, AL ... Medical Genetics (ACMG), the national professional organization for medical ... President Joe Leigh Simpson, MD, FACMG, of Miami, FL ...
... April 14 Continuing a nine-year tradition of putting ... Lines (NYSE: DAL ) employees today presented ... gift of more than 1,250 handmade quilts. Each quilt, ... airline employees and other volunteers on their own time.(Logo: ...
Cached Medicine News:Health News:Clinical Diagnostic Lab Testing Market to Grow Over 90% through 2017 2Health News:Clinical Diagnostic Lab Testing Market to Grow Over 90% through 2017 3Health News:SOKO Fitness & Spa Group, Inc. to hold 2009 Q3 Earnings Call on Apr. 16 2Health News:Nearly 18 Million Will Have Macular Degeneration by 2050 2Health News:Nearly 18 Million Will Have Macular Degeneration by 2050 3Health News:Bruce R. Korf, MD, PhD is Named President of the American College of Medical Genetics 2Health News:Bruce R. Korf, MD, PhD is Named President of the American College of Medical Genetics 3Health News:Delta Employees Blanket Salt Lake City Medical Center With Warm Gifts 2
Innotrac Aio! immunoanalyzers are specially designed to exploit the benefits of Innotrac Diagnostics' exclusive dry chemistry and non-enhancement time-resolved fluorometry....
... Synchron LXi 725 clinical system combines ... accurate immunoassay testing capabilities, innovative data ... a single platform. After tests are ... for optimal quality assurance. If reflex ...
... Access immunoassay system is ... benchtop analyzer that performs ... with panels that include ... infectious disease, blood virus, ...
...
Medicine Products: